Can-Fite BioPharma (CANF): Utang-utang marang kapitalisasi buku

Can-Fite BioPharma (CANF) is scaling its oncology therapy through licensing agreements and patent acquisitions. The debt-to-capitalization ratio reflects the capital structure dynamics, where 0.01 represents the current metric. Growth is supported by psoriasis and MASH trials, as well as FDA approval, which strengthens physician confidence and investor loyalty to the brand's scientific profile.

The reliability of equity assets is assessed through the balance of liabilities and equity. This indicator measures the share of total debt in the company's book value, determining the level of financial leverage. For Can-Fite BioPharma (CANF), with its unique patent developments, low debt confirms the resilience of the business model. Stable drug sales minimize credit risks. An analysis of the ratio between total liabilities and book capitalization confirms management discipline.